top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Stephen Ray Mitchell net worth and biography

Stephen Mitchell Biography and Net Worth

Director of Vanda Pharmaceuticals

Dr. Mitchell currently serves as the Joseph Butenas Professor and Dean for Medical Education at Georgetown University School of Medicine, a position he has held since August 2002. Prior to that, Dr. Mitchell served as Associate Dean for Clinical Curriculum at Georgetown University School of Medicine from 1998 to 2000 and as Senior Associate Dean for Academic Affairs from 2000 until 2002. Previously, Dr. Mitchell served as Program Director for Internal Medicine at Georgetown University School of Medicine from 1992 until 1997, and as Founding Program Director Med-Peds at Georgetown from 1995 until 1999. He served as a member of the Liaison Committee for Medical Education (the “LCME”), the national accrediting body for Medical Schools in the United States and Canada, between 2013 and 2019. Since 2018, he has held the role of Chair of the LCME, where he chaired the Standards subcommittee, and now serves as a member of the Governing Council of that body. Dr. Mitchell is a veteran of the United States Air Force, and has served as author and invited external reviewer on Studies by the Institute of Medicine on Chronic Multi-symptoms illness in Gulf War veterans. Dr. Mitchell received his B.A. in Psychology and his M.D. from the University of North Carolina at Chapel Hill, and his Global Executive M.B.A. from The McDonough School of Business at Georgetown University.

What is Stephen Ray Mitchell's net worth?: The estimated net worth of Stephen Ray Mitchell is at least $136,375.20 as of August 10th, 2023. Dr. Mitchell owns 29,328 shares of Vanda Pharmaceuticals stock worth more than $136,375 as of April 24th. This net worth estimate does not reflect any other assets that Dr. Mitchell may own. Learn More about Stephen Ray Mitchell's net worth.
How do I contact Stephen Ray Mitchell?: The corporate mailing address for Dr. Mitchell and other Vanda Pharmaceuticals executives is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. Vanda Pharmaceuticals can also be reached via phone at (202) 734-3400 and via email at [email protected]. Learn More on Stephen Ray Mitchell's contact information.
Has Stephen Ray Mitchell been buying or selling shares of Vanda Pharmaceuticals?: Stephen Ray Mitchell has not been actively trading shares of Vanda Pharmaceuticals during the past quarter. Most recently, Stephen Ray Mitchell sold 6,500 shares of the business's stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $6.05, for a transaction totalling $39,325.00. Following the completion of the sale, the director now directly owns 29,328 shares of the company's stock, valued at $177,434.40. Learn More on Stephen Ray Mitchell's trading history.
Who are Vanda Pharmaceuticals' active insiders?: Vanda Pharmaceuticals' insider roster includes Phaedra Chrousos (Director), Aranthan Jones, II (Insider), Stephen Mitchell (Director), Kevin Moran (CFO), Mihael Polymeropoulos (CEO), and Joakim Wijkstrom (CMO). Learn More on Vanda Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vanda Pharmaceuticals?: In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 43,036 shares worth more than $271,424.76. The most recent insider tranaction occured on August, 21st when CMO Joakim Wijkstrom sold 3,724 shares worth more than $21,748.16. Insiders at Vanda Pharmaceuticals own 7.7% of the company. Learn More about insider trades at Vanda Pharmaceuticals.
Information on this page was last updated on 8/21/2023.

Stephen Ray Mitchell Insider Trading History at Vanda Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/10/2023	Sell	6,500	$6.05	$39,325.00	29,328
6/13/2022	Sell	2,700	$9.48	$25,596.00	6,515
9/9/2021	Sell	19,109	$16.74	$319,884.66	15,200

Stephen Ray Mitchell Buying and Selling Activity at Vanda Pharmaceuticals

Vanda Pharmaceuticals Company Overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Today's Range

Now: $4.56

$4.55

$4.67

50 Day Range

MA: $4.27

$3.75

$5.24

2 Week Range

Now: $4.56

$3.30

$7.00

Volume

1,183,979 shs

Average Volume

2,078,668 shs

Market Capitalization

$262.38 million

P/E Ratio

91.22

Dividend Yield

N/A

Beta

0.76